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likely account for the safety and efficacy demonstrated in our series.
Heparin administration to patients in whom dabigatran has not
been fully interrupted might be expected to lead to increased
bleeding complications due to a probable drug-drug interaction
and poor absorption post-ablation might lead to increased throm-
boembolic events. The convenience of standardized oral dosing
and elimination of INR monitoring makes dabigatran and other
new oral anticoagulants attractive alternates to warfarin for AF
ablation patients.
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Reply
We appreciate the interest of Dr. Winkle and colleagues in our
recent study on the safety of periprocedural dabigatran during
atrial fibrillation (AF) ablation (1). We do concur with some of the
comments made by Dr. Winkle and colleagues and would like to
add some more information to help us all better understand this
important aspect of periprocedural anticoagulation during AF
ablation.
1. The in vitro interaction of simultaneously administered dabigatran
and heparin is well known and is probably an extension of their
pharmacodynamic properties. However, starting parenteral hepa-
rin 12 h after the last dose of dabigatran is considered reasonably
safe for bridging anticoagulation before any invasive procedure,
as supported by the safety profile in more than 600 patients who
were bridged in the Re-Ly trial, and is currently recommended
(2). The approximate mean time from the last dose of dabiga-
tran to intravenous administration of heparin was 16 h. Asmentioned in our paper, the reason for the increased bleeding
outcomes in our study may still partly be explained by the
interaction between unfractionated heparin and the residual
dabigatran effect at the time of the procedure.
2. The absorption of dabigatran after hip surgery can be delayed
and potentially reduced in a minority of patients as shown by an
increase in the time to peak and a decrease in the peak plasma
levels (3). However, the therapeutic effect of the drug can be
seen at 50% of the peak plasma level. These differences in the
plasma levels after a hip surgery are probably not clinically
significant as evidenced by multiple trials showing either
noninferiority or superiority of dabigatran when compared with
heparin in preventing venous thromboembolism in post-
operative settings (4).
3. We do recognize that the lack of a direct antidote to dabigatran
could make the management of bleeding episodes difficult.
However, the same is true for subcutaneous enoxaparin, which
was the primary anticoagulant used for bridging patients to
dabigatran by Dr. Winkle and colleagues.
There is overwhelming data to support much better outcomes
when AF ablation is done on therapeutic warfarin when compared
to the interrupted approach (5,6). When enoxaparin is used for
bridging, the bleeding complications normally occur after dis-
charge and might not be captured unless an appropriate data
collection system is in place and the thromboembolic complica-
tions (in 1% to 5% of patients) tend to be clustered in nonparox-
ysmal AF cases (5). Therefore, the lack of thromboembolic
complications in Dr. Winkle and colleagues series could be due to
either a different patient selection or a limited ablation lesion set,
which may be inadequate to achieve freedom from atrial arrhyth-
mias in the nonparoxysmal group.
We do hope that the newer anticoagulants (rivaroxaban and
apixaban), with their slightly different pharmacokinetic and phar-
macodynamic profile, would be safer than dabigatran in this
setting. Future studies evaluating these drugs as periprocedural
anticoagulants for AF ablation are urgently needed.
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What’s Contrasting Contrast?
I read with interest the recently published paper by Greupner et al.
(1), and would like to comment on the surprising absence of
contrast echocardiography among the tested methods for volume
and ejection fraction measurement.
At least 2 previously published studies, which were not appro-
priately referenced and discussed in the paper, conducted in wider
samples (120 and 50 subjects, respectively), demonstrated that
both 2- and 3-dimensional echocardiograms benefit significantly
from contrast administration in terms of accuracy and reduced
interobserver variability compared with standard echocardiography
and cardiac magnetic resonance, as long as volumes and ejection
fraction measurements are considered (2,3).
Furthermore, the study byHoffmann et al. (2) was amulticenter study,
and demonstrated that the interobserver variability of contrast echocar-
diography (both mean percentage of error and intraclass correlation) for
ejection fraction was even lower than that of cardiac magnetic resonance,
which is usually considered the reference method.
Why was there no testing of echocardiography with contrast,
which is cheap, widely available, and approved for endocardial
border enhancement indication?
A slightly modified old-fashioned ultrasound technique has the
potential to outperform more costly, glittering, and technically
demanding techniques, or at least it should be given a fair chance.
This happens in front of the widespread urge to cut the world
health costs, and a clear and common sense European Union
European Atomic Energy Community directive, which compels
the use of nonradiating diagnostic methods in medicine when they
can be used in substitution of methods using ionizing radiations.
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Reply
We found the comments of Dr. Gaibazzi very thoughtful. We
certainly agree that echocardiography should be the “first line”
technique for evaluation of left ventricular function because it is widely
available, easily done, very cost efficient, and does not require ionizing
radiation. Furthermore, contrast media are a possible way to improve
the diagnostic performance of echocardiography (1,2). However,
there is also evidence that computed tomography (CT) shows better
reproducibility and accuracy than contrast-enhanced (CE) echocardi-
ography (3,4) and may be favored in certain patients (e.g., those with
deformed ventricular anatomy).
To address this issue, we also included 2-dimensional (2D) CE
echocardiography in our study. To stay as close to everyday clinical
practice, we left the decision to administer contrast media to the
cardiologist depending on the quality of the acoustic window for
echocardiography. Only 7 of 36 patients underwent 2D CE
echocardiography. In this, albeit small, subgroup of our study,
there was no significant difference in the Bland-Altman analysis of
ejection fraction (EF) and stroke volume for CT, 2D echocardio-
graphy and 2D CE echocardiography compared with magnetic
resonance imaging (MRI) as the reference standard. We found
significantly smaller end-diastolic volume (EDV) and end-systolic
volume (ESV) in 2D echocardiography and 2D CE echocardio-
graphy compared with MRI as the reference standard (Table 1). How-
ever, only 2D echocardiography showed significantly larger limits of
agreement for EDV than CT. In addition, although there was a trend
toward smaller limits of agreement for 2D CE echocardiography, we
found no significant improvement compared with 2D echocardiography.
Therefore, our small cohort indicates that contrast improves the
accuracy of echocardiography, whereas CT is more accurate than
Left Ventricular Function Parameters inthe 7 Patients Who Underwent CE Echocardiography
Table 1
Left Ventricul r Function Parameters in
the 7 Patients Who Underwent CE Echocardiography
MRI CT 2D Echo 2D CE Echo
EF, % 61.5 5.3 62.7 9.9 61.6 9.9 65.5 4.6
EDV, ml 116.5 29.0 126.0 33.3* 81.4 29.4* 94.2 25.9*
ESV, ml 45.7 16.5 47.4 18.8 31.3 12.0* 32.2 9.4*
SV, ml 70.8 14.3 78.6 25.2 50.1 20.3 62.0 18.4
*p  0.05, Wilcoxon test versus MRI.
CE  contrast enhanced; CT  computed tomography; Echo  echocardiography; EDV 
nd-diastolic volume; EF  ejection fraction; ESV  end-systolic volume; MRI  magnetic
esonance imaging; SV  stroke volume; 2D  two-dimensional.
